Kinase inhibitors in clinical practice: An expanding world

Journal of Allergy and Clinical Immunology

Volumn 141, Issue 2, 2018, Pages 522-524

  Pandey, Ruchi ^a   Kapur, Reuben ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immune disorders; IPI 549; Kinase inhibitors; phosphoinositide 3 kinase

Indexed keywords

DASATINIB; IDELALISIB; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR;

AUTOIMMUNE DISEASE; CLINICAL PRACTICE; EDITORIAL; HUMAN; PRIORITY JOURNAL; ENZYMOLOGY; IMMUNOLOGY; IMMUNOPATHOLOGY; URINE;

HUMANS; IMMUNE SYSTEM DISEASES; PROTEIN KINASE INHIBITORS;

EID: 85030859814     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.07.016     Document Type: Editorial

References (9)

1. Bower, H., Bjorkholm, M., Dickman, P.W., Hoglund, M., Lambert, P.C., Andersson, T.M., Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34 (2016), 2851–2857.
2. Sogi, M.K., Lien, K.A., Johnson, J.R., Krogan, N.J., Stanley, S.A., The tyrosine kinase inhibitor Gefitinib restricts Mycobacterium tuberculosis growth through increased lysosomal biogenesis and modulation of cytokine signaling. ACS Infect Dis, 2017 [Epub ahead of print].
3. Arend, K.C., Lenarcic, E.M., Vincent, H.A., Rashid, N., Lazear, E., McDonald, I.M., et al. Kinome profiling identifies druggable targets for novel Human Cytomegalovirus (HCMV) antivirals. Mol Cell Proteomics 4:suppl 1 (2017), S263–S276.
4. Hekim, C., Ilander, M., Yan, J., Michaud, E., Smykla, R., Vähä-Koskela, M., et al. Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models. Cancer Immunol Res 5 (2017), 157–169.
5. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
6. Maffei, R., Fiorcari, S., Martinelli, S., Potenza, L., Luppi, M., Marasca, R., Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib. J Hematol Oncol, 8, 2015, 60.
7. De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539 (2016), 443–447.
8. Kaneda, M.M., Messer, K.S., Ralainirina, N., Li, H., Leem, C.J., Gorjestani, S., et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 539 (2016), 437–442.
9. Compagno, M., Wang, Q., Pighi, C., Cheong, T.C., Meng, F.L., Poggio, T., et al. Phosphatidylinositol 3-kinase delta blockade increases genomic instability in B cells. Nature 542 (2017), 489–493.